中心性漿液性脈絡網膜症に対するベバシズマブ硝子体注入治療

Intravitreal injection of bevacizumab in the treatment of central serous chorioretinopathy

要約　目的：ベバシズマブ硝子体注入による中心性漿液性脈絡網膜症の治療成績の報告。対象と方法：中心性漿液性脈絡網膜症が再発し，3か月以上治癒しない7例7眼を対象とした。男性5例，女性2例で，年齢は30～61歳（平均44歳）である。ベバシズマブ1.25mgを硝子体に注入し，平均14.5か月の経過を追った。結果：硝子体注入後3か月以内に4例で漿液性網膜剝離が消失し，光干渉断層計で確認できた。他の3眼にはベバシズマブを追加投与し，2例で初回投与から4か月以内，1例で12か月以内に網膜剝離が消失した。全7例での網膜剝離消失までの期間は平均3.8か月であった。全例で12か月後の視力は改善または維持された。フルオレセインとインドシアニングリーン蛍光造影による過蛍光点と蛍光漏出は治療後に減少した。結論：中心性漿液性脈絡網膜症の再発に対するベバシズマブの硝子体注入は有効であった。

Abstract.　Purpose：To report the outcome of intravitreal injection of bevacizumab for central serous chorioretinopathy（CSC）. Cases and Method：This study was made on 7 eyes of 7 patients who had recurrence of CSC persisting for 3 months or longer. The series comprised 5 males and 2 females. The age ranged from 30 to 61 years,average 44 years. They were treated by intravitreal injection of 1.25 mg bevacizumab and were followed up for an average of 14.5 months. Results：CSC disappeared in 4 cases within 3 months of treatment. The finding was confirmed by optical coherence tomography. The other 3 cases received repeat injection. CSC disappeared in 2 cases within 4 months after the initial treatment and in one case within 12 months. CSC disappeared after an average of 3.8 months in the whole series. Visual acuity improved or was maintained in all the 7 cases after 12 months of treatment. Hyperfluorescence and dye leakage decreased after treatment when seen by fluorescein or ICG angiography. Conclusion：Intravitreal injection of bevacizumab was effective for recurrence of CSC.